ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study evaluates safety and tolerability of endolysin-derived LSVT-1701 (tonabacase) as
an add-on to standard of care (SOC) antibiotic therapy for the treatment of patients with
complicated Staphylococcus aureus bacteremia (SAB), including left- and right-sided infective
endocarditis (IE).